Showing 9621-9630 of 20328 results for "".
- AI Dermatology Tools Improve Patient Diagnostic Accuracy in Survey Studyhttps://reachmd.com/news/ai-dermatology-tools-improve-patient-diagnostic-accuracy-in-survey-study/2486637/An AI-powered dermatology application was associated with improved consumer understanding of skin conditions, according to new research published in JAMA Dermatology. The study includ
- Remimazolam Matches Propofol In Postoperative ICU Sedation Trialhttps://reachmd.com/news/remimazolam-matches-propofol-in-postoperative-icu-sedation-trial/2486614/A paper reports results from a multicenter, randomized, single-blind, actively controlled phase 3 non-inferiority trial comparing remimazolam tosylate with propofol, with sedation success rates
- Analysis: No Lymphoma Signal With Topical Calcineurin Inhibitorshttps://reachmd.com/news/analysis-no-lymphoma-signal-with-topical-calcineurin-inhibitors/2486626/A recent pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database found no significant association between topical calcineurin inhibitors (TCIs) and lymphoma, despite longstanding boxed warnings in the United States.
- Interim IIT Data Explore Sculptra, Restylane for Menopause, Weight Loss–Related Aesthetic Changeshttps://reachmd.com/news/interim-iit-data-explore-sculptra-restylane-for-menopause-weight-lossrelated-aesthetic-changes/2486595/Interim findings from 2 ongoing investigator-initiated trials supported by Galderma suggest potential roles for Sculptra and the Restylane portfolio in treating aesthetic changes associated with menopause and medication-driven weight loss. In one interim analysis led by Sabrina Fabi, MD, 2
- Ucla Listing Details Phase 2 Ianalumab Study In DcSSchttps://reachmd.com/news/ucla-listing-details-phase-2-ianalumab-study-in-dcssc/2486578/Key Takeaways: The listing describes an actively recruiting phase 2 placebo-controlled study of subcutaneous ianalumab in diffuse cutaneous systemic sclerosis. Enrollment is limited by protocol-defined diagnosis, age, disease-duration, and baseline ski
- Central Pathology Review Finds Discordance In LNG IUD Trialhttps://reachmd.com/news/central-pathology-review-finds-discordance-in-lng-iud-trial/2486579/Key Takeaways: Interobserver agreement was reported at baseline and at both post-treatment timepoints. Discordance was reported more often in site-labeled hyperplasia than adenocarcinoma, and discordant cases were frequently upgraded on central review.
- Ketamine Trial Finds No Recovery Benefit, Higher ICU Transferhttps://reachmd.com/news/ketamine-trial-finds-no-recovery-benefit-higher-icu-transfer/2486580/Key Takeaways: Ketamine in major abdominal ERAS care was reported not to reduce hospital length of stay or opioid use versus placebo. In this trial, ketamine was associated with lower odds of meeting early discharge milestones and higher odds of ICU tr
- Study Links Vitiligo to Higher Autoimmune and Infection Burden in US Cohorthttps://reachmd.com/news/vitiligo-linked-to-higher-autoimmune-and-infection-burden-in-us-cohort/2486572/New data from a large retrospective study suggested patients with vitiligo experience higher rates of several comorbidities and safety events compared with matched controls. Investigators analyzed Optum Market Clarity EHR dat
- ELEVATE-IPF: New Findings on Deupirfenidonehttps://reachmd.com/news/elevate-ipf-deupirfenidone/2486553/Key Takeaways ELEVATE-IPF randomized patients to deupirfenidone 550 mg, deupirfenidone 825 mg, pirfenidone 801 mg, or placebo. Less FVC decline was reported for combined deupirfenidone versus placebo, and a separate frequentist analysis also reported l
- Navigated TMS Trial Reports PTSD Symptom Improvementhttps://reachmd.com/news/navigated-tms-ptsd-symptom-improve/2486556/Key Takeaways Adjunctive navigated TMS was associated with greater reported PTSD symptom improvement than sham in this randomized trial population. Improvement was reported at one month, and group differences were also reported at three months. </